Novo Nordisk A/SNVONYSE
Loading
Interest Expense Over TimeExpanding
Percentile Rank100
3Y CAGR+158.3%
5Y CAGR+67.1%
Studio
Year-over-Year Change

Interest expense on outstanding debt

3Y CAGR
+158.3%/yr
vs +45.2%/yr prior
5Y CAGR
+67.1%/yr
Recent acceleration
Acceleration
+113.1pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
13x
Strong expansion
Streak
4 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$6.52B+297.4%
2024$1.64B+202.6%
2023$542.00M+43.4%
2022$378.00M+30.8%
2021$289.00M-42.3%
2020$500.84M+1.3%
2019$494.47M+481.7%
2018$85.00M-5.6%
2017$90.00M+38.5%
2016$65.00M-